Illumina Inc. has entered into a multi-year licensing agreement with Quest Diagnostics, related to the use of Illumina's next-generation sequencing, or NGS, technology for clinical laboratory testing. Among the terms, Quest will have broad rights to use Illumina's sequencing and genotyping technology, including the MiSeq platform and related consumables, to develop, validate and offer molecular laboratory-developed tests for several disease states to clinicians in the US. Quest also has rights to use the Illumina equipment as biomarker test services in clinical trials performed on behalf of its pharmaceutical, biotechnology and other clients.